Skip to content

The molecular markers screening about Apatinib in the anti-angiogenesis treatment of advanced gastric cancer

The molecular markers screening about Apatinib in the anti-angiogenesis treatment of advanced gastric cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027685
Enrollment
Unknown
Registered
2019-11-23
Start date
2019-12-15
Completion date
Unknown
Last updated
2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Case series:Nil

Sponsors

Bangwei Cao
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. In patients with advanced gastric cancer who have failed to be diagnosed by pathology and/or cytology, at least one evaluable target lesion with a scale measurement of >= 1.0 cm; 2. aged >= 18 years old; 3. ECOG physical status score is 0-2; 4. Life expectancy after the start of administration of the study drug >= 12 weeks; 5. The function of each organ meets the following criteria: AST, ALT = 1500 /uL; platelets >= 80,000/uL, hemoglobin >= 80 g/L; 6. Informed consent has been signed for the name and time, indicating that the patient has been informed of all relevant matters prior to enrollment; 7. Patients using anticoagulants must meet the following conditions within 7 days of treatment: INR < 1.5 and APTT < 1.5 ULN.

Exclusion criteria

Exclusion criteria: 1. Currently receiving other anti-tumor treatments (including radiotherapy); 2. Renal insufficiency: creatinine clearance 2+ patients should be measured 24h urine collection, and must be confirmed protein / 24 hours 150 mmHg and / or diastolic blood pressure > 100 mmHg) or clinically significant (such as active) cardiovascular disease (6 months before enrollment), myocardial infarction (6 months before enrollment)), unstable angina, NYHA grade II or higher congestive heart failure, or severe arrhythmia can not be controlled by drugs or have potential effects on trial treatment; 5. History or examination results indicate the presence of hereditary bleeding tendency or coagulopathy; 6. Severe or unhealed wounds, peptic ulcers or (healed incomplete) fractures; 7. Active gastrointestinal bleeding, gastrointestinal perforation or abdominal abscess; 8. Pregnant or lactating patients; 9. Patients with severe medical problems, such as cardiac dysfunction or related history such as myocardial infarction or severe arrhythmia history.

Design outcomes

Primary

MeasureTime frame
DCR;

Countries

China

Contacts

Public ContactBangwei Cao

Beijing Friendship Hospital, Capital Medical University

daweicao@163.com+86 13021161027

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026